Workflow
Price target
icon
Search documents
Wall Street Analysts Think Hecla Mining (HL) Could Surge 26.12%: Read This Before Placing a Bet
ZACKS· 2025-07-21 14:56
Core Viewpoint - Hecla Mining (HL) shows potential for upside based on Wall Street analysts' short-term price targets, with a mean target of $7.34 indicating a 26.1% upside from the current price of $5.82 [1] Price Targets and Estimates - The average price target consists of eight estimates ranging from a low of $5.50 to a high of $11.50, with a standard deviation of $1.85, indicating variability among analysts [2] - The lowest estimate suggests a decline of 5.5%, while the highest indicates a potential upside of 97.6% [2] - Analysts' consensus on price targets should be approached with caution, as their ability to set unbiased targets has been questioned [3][7] Earnings Estimates - Analysts are optimistic about HL's earnings prospects, with a consensus indicating better earnings than previously estimated [4] - Over the last 30 days, one estimate has increased, leading to a 11.1% rise in the Zacks Consensus Estimate for the current year [12] - HL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Analyst Agreement - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction [9] - While price targets should not be the sole basis for investment decisions, they can provide a starting point for further research into fundamental drivers [10][14]
Wall Street Analysts Think Alamos Gold (AGI) Could Surge 27.6%: Read This Before Placing a Bet
ZACKS· 2025-07-07 14:55
Core Viewpoint - Alamos Gold (AGI) shows potential for upside with a mean price target of $34.44, indicating a 27.6% increase from the current price of $26.99 [1] Price Targets and Analyst Consensus - The average price target consists of 10 estimates ranging from a low of $23.74 to a high of $38.36, with a standard deviation of $4.17, suggesting variability in analyst predictions [2] - The lowest estimate indicates a potential decline of 12%, while the highest suggests a 42.1% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about AGI's earnings prospects, with a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has increased by 12.5% over the past month, with two estimates rising and one falling [12] - AGI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know
ZACKS· 2025-06-11 15:00
Group 1 - Monopar Therapeutics Inc. (MNPR) closed at $34.51, with a 2% gain over the past four weeks, and a mean price target of $52.20 indicating a 51.3% upside potential [1] - The average price targets range from a low of $37 to a high of $76, with a standard deviation of $15.69, suggesting variability in analyst estimates [2] - Analysts show strong agreement on MNPR's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 15.2% over the past month, with two estimates going higher and no negative revisions [12] - MNPR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate potential price movement direction [10][13]
Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade
ZACKS· 2025-06-04 15:01
Core Viewpoint - Amneal Pharmaceuticals (AMRX) shows potential for significant upside, with a mean price target of $11.50 indicating a 54.4% increase from its current price of $7.45 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $0.58, suggesting a consensus among analysts [2]. - The lowest price target is $11, representing a 47.7% increase, while the highest target is $12, indicating a 61.1% potential rise [2]. - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown growing optimism about AMRX's earnings prospects, as evidenced by upward revisions in EPS estimates [11]. - Over the past 30 days, the Zacks Consensus Estimate for the current year has increased by 1.1%, with one estimate moving higher and no negative revisions [12]. - AMRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Caution on Price Targets - Solely relying on price targets for investment decisions may not be prudent, as analysts' price targets can often be overly optimistic due to business incentives [3][8]. - While price targets can provide insights, they should be approached with skepticism and not be the sole basis for investment decisions [10].
Wall Street Analysts Predict a 44.7% Upside in Contango ORE, Inc. (CTGO): Here's What You Should Know
ZACKS· 2025-06-03 14:56
Group 1 - Contango ORE, Inc. (CTGO) closed at $20.27, with a 45.4% gain over the past four weeks, and a mean price target of $29.33 suggests a 44.7% upside potential [1] - The average price target ranges from a low of $26 to a high of $32, with a standard deviation of $3.06, indicating a potential increase of 28.3% to 57.9% from the current price [2] - Analysts show strong agreement on CTGO's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for CTGO's current year earnings has increased by 176.9% over the last 30 days, with no negative revisions [12] - CTGO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement, which appears to be a good guide for potential upside [13]
Wall Street Analysts Predict a 28.13% Upside in Energy Transfer LP (ET): Here's What You Should Know
ZACKS· 2025-05-19 14:56
Core Viewpoint - Energy Transfer LP (ET) shows potential for significant upside, with a mean price target of $23 indicating a 28.1% increase from the current price of $17.95 [1] Price Targets and Analyst Consensus - The average price target for ET is based on 15 short-term estimates, ranging from a low of $19 to a high of $26, with a standard deviation of $1.96, suggesting a moderate agreement among analysts [2] - The lowest estimate indicates a 5.9% increase, while the highest suggests a 44.9% upside, highlighting the variability in analyst predictions [2][9] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding ET's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the past 30 days, two earnings estimates for ET have been revised upward, resulting in a 1.9% increase in the Zacks Consensus Estimate [12] Zacks Rank and Investment Potential - ET holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13]
X @CryptoJack
CryptoJack· 2025-05-14 08:01
What’s your dream price target for #ETH this year? 🪙 ...
Wall Street Analysts Predict a 26.55% Upside in Arista Networks (ANET): Here's What You Should Know
ZACKS· 2025-05-12 15:01
Core Viewpoint - Arista Networks (ANET) has shown a significant price increase of 19.1% over the past four weeks, with a mean price target of $109.49 indicating a potential upside of 26.6% from the current price of $86.52 [1] Price Targets and Estimates - The mean estimate consists of 18 short-term price targets with a standard deviation of $14.99, suggesting variability in analyst predictions. The lowest estimate is $87 (0.6% increase), while the highest is $130 (50.3% increase) [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] Analyst Sentiment and Earnings Estimates - Analysts have shown increasing optimism about ANET's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 4.5%, with seven estimates moving higher and no negative revisions [12] Zacks Rank and Investment Potential - ANET holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [13]
How Much Upside is Left in California BanCorp (BCAL)? Wall Street Analysts Think 25.39%
ZACKS· 2025-05-05 15:01
Group 1 - California BanCorp (BCAL) closed at $14.89, with a 19.6% gain over the past four weeks, and a mean price target of $18.67 suggests a 25.4% upside potential [1] - The mean estimate includes three short-term price targets with a standard deviation of $0.58, indicating a low variability among analysts [2] - Analysts have shown increasing optimism regarding BCAL's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for BCAL has increased by 3.3% due to one upward revision in earnings estimates over the last 30 days [12] - BCAL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While the consensus price target may not be a reliable indicator of the extent of gains, it does provide a directional guide for price movement [13]
Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet
ZACKS· 2025-04-30 15:00
Core Viewpoint - Immunocore Holdings PLC (IMCR) has seen a 6.4% increase in share price over the past four weeks, closing at $30.47, with analysts suggesting a potential upside of 107.5% based on a mean price target of $63.21 [1] Price Targets - The average of 14 short-term price targets ranges from a low of $24 to a high of $100, with a standard deviation of $23.20, indicating variability among analysts [2] - The lowest estimate suggests a decline of 21.2% from the current price, while the highest estimate indicates a potential upside of 228.2% [2] Analyst Consensus and Earnings Estimates - Analysts are increasingly optimistic about IMCR's earnings prospects, as evidenced by a strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [4][11] - The Zacks Consensus Estimate for the current year has risen by 3.9% over the past month, with one estimate increasing and no negative revisions [12] Zacks Rank - IMCR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]